和铂医药-B首予“跑赢行业”评级,目标价13.4港元

中金公司
Jul 31, 2025

一、首次覆盖与评级目标中金公司 发布研报,首次覆盖和铂医药-B(02142),给予“跑赢行业”评级,并设定了13.4港元的目标价。同时,中金预计公司在2025年至2026年的每股盈利分别为0.09元和0.02元人民币。这一评级反映了中金对和铂医药未来发展的积极预期。二、核心技术平台的竞争力报告指出,和铂医药拥有自主知识产权的全人源单抗转基因鼠系列核心技术平台,并完成了从1.0到2.0的技术升级。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10